Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2011-08-30
2011-08-30
Bristol, Lynn (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C530S389100
Reexamination Certificate
active
08007794
ABSTRACT:
The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
REFERENCES:
patent: 2004/0110170 (2004-06-01), Pisegna et al.
patent: 2005/0234054 (2005-10-01), Mueller et al.
patent: WO 2004/003019 (2004-06-01), None
ATCC website search for PTA-6867 deposit (p. 1; Oct. 22, 2010).
ATCC website search for PTA-6866 deposit (p. 1; Oct. 22, 2010).
MacCallum et al. (J. Mol. Biol. (1996) 262:732-745)).
Casset et al. (BBRC 307, 198-205, (2003)).
Holm et al. (Mol. Immunol. 44: 1075-1084 (2007)).
Chen et al. (J. Mol. Bio. 293, 865-881 (1999)).
De Pascalis et al. (The Journal of Immunology (2002) 169, 3076-3084).
Vajdos et al. ((2002) J. Mol. Biol. 320, 415-428).
Wu et al. (J. Mol. Biol. (1999) 294, 151-162).
Ward et al. (Nature 341:544-546 (1989)).
Smith-Gill et al. (J. Immunol. 139:4135-4144 (1987)).
Kumar et al. (J. Biol. Chem. 275:35129-35136 (2000)).
Song et al. (Biochem Biophys Res Comm 268:390-394 (2000)).
Dufner (Trends Biotechnol. 24(11):523-29 (2006)).
Brummell et al. (Biochemistry 32:1180-1187 (1993)).
Kobayashi et al. (Protein Engineering 12:879-844 (1999)).
Burks et al. (PNAS 94:412-417 (1997)).
Jang et al. (Molec. Immunol. 35:1207-1217 (1998)).
Brorson et al. (J. Immunol. 163:6694-6701 (1999)).
Coleman (Research in Immunol. 145:33-36 (1994)).
Frobert Y et al: “A sensitive sandwich enzyme immnoassay for calcitonin gene-related peptide (CGRP)” Peptides 1999, vol. 20, No. 2, 1999, pp. 275-284.
Tan K K et al:“Calcitonin gene-related peptides as an endogenous vasodilator:immunoblockade . . . ”, Clinical Science(London,Englad:1979)Dec. 1995, vol. 89, No. 6, Dec. 1995,pp. 565-573.
Buckley T L et al: “The partial inhibition of inflammatory responses induced by capsaicin using the FAB frag . . . ”Neuroscience, New York, NY,US, vol. 48, No. 4, 1992, pp. 963-968.
Balint R F et al: Antibody Engineering by Parsimonious Mutagenesis: Gene, Elsevier, Amsterdam, NL, vol. 137, No. 1, Dec. 27, 1993, p. 109-118.
Little M et al: :Of mice and men; hybridoma and recombinant antibodies Immunology Today, Elsevier publications, Cambridge. GB, vol. 21, No. , Aug. 1, 2000, vol. 21, No. 8.
Holt L J et al: Domain Antibodies: Proteins for Therapy: Trends in Biotechnology, Elsevier Publications, Cambridge, GB, vol. 21, No. 11, Nov. 2003 pp. 484-490.
Davies J et al: “Affinity improvement of single antibody VH domains: residues . . . ” Imnnunotechnology, Elsevier Science Publishers BV, NL, v.2, No. 3, Sep. 1996 pp. 169-179.
Abdiche Yasmina Noubia
Collier Sierra Leigh Jones
Pons Jaume
Poulsen Kristian T.
Rosenthal Arnon
Bristol Lynn
Kispert Jennifer
Lodovice Ian J. S.
Rinat Neuroscience Corporation
LandOfFree
Antagonist antibodies directed against calcitonin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antagonist antibodies directed against calcitonin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antagonist antibodies directed against calcitonin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2782350